You are viewing an expired study

This study is not currently recruiting Study Participants on If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Seattle, Washington 98105

  • Postoperative Complications


OBJECTIVES: I. Determine the pharmacokinetics of ketorolac in infants following surgery. II. Determine the analgesic efficacy of this drug, in terms of infant pain score, time to first opiate medication, and total opioid administration, in these patients. III. Determine the toxicity of this drug in these patients.

Study summary:

PROTOCOL OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to age (0-7 days vs 8-30 days vs 31-90 days vs 91-180 days vs 181-365 days vs 12-18 months). Patients are randomized to one of three treatment arms. Arm I: Patients receive low-dose ketorolac IV over 10 minutes on postoperative day 1 and morphine IV every 1-4 hours as needed. Treatment with ketorolac may continue every 8 hours for 2 days. Arm II: Patients receive high-dose ketorolac and morphine as in arm I. Arm III: Patients receive normal saline IV over 10 minutes on postoperative day 1 and morphine as in arm I. Patients in all arms are assessed for pain score every 2 hours for 4 hours prior to treatment and for 12 hours after treatment.


PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Full-term infants (at least 36 weeks gestation at birth) who are scheduled for one of the following surgeries requiring hospital admission postoperatively: exploratory laparotomy, pyloromyotomy, cleft lip repair, cleft palate repair, craniectomy, placement of ventriculo-peritoneal shunts, urologic surgery (with normal renal function), orthopedic procedures No post-operative analgesia managed with ongoing epidural infusions; single dose caudal epidural injections given intraoperatively allowed --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: See Disease Characteristics Other: No concurrent gastrotonic agents such as reglan or cisapride; no concurrent coumadin or therapeutic heparin --Patient Characteristics-- Performance status: Not specified Hematopoietic: No patient or family history of bleeding or coagulation defects Hepatic: Hepatic function normal; no prior hepatic transplantation Renal: Renal function normal; no prior renal transplantation Other: No history of gastrointestinal bleeding; no closure of large gastroschisis or omphalocele defects (with increased intra-abdominal pressure); no prior repair of diaphragmatic hernia; no allergy to ketorolac



Primary Contact:

Study Chair
Anne M. Lynn
Seattle Children's Hospital

Backup Contact:


Location Contact:

Seattle, Washington 98105
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.